Psoriasis is a consistently recurring, inflammatory skin disease, affecting about 2-5% of the
world population. Different types of psoriasis can be observed such as guttate psoriasis …

The systemic therapies available for the management of Psoriasis (PsO) patients who
cannot be treated with more conservative options, such as topical agents and/or …

1.1 Bedarfsanalyse/Probleme in der Versorgung der Patienten Die Psoriasis vulgaris stellt
eine häufige und fast immer chronisch verlaufende dermatologische Erkrankung dar. Die …

Psoriasis vulgaris is a common, chronic inflammatory skin disease with a prevalence of 1.5-
2% in Western industrialized countries. A relevant percentage of patients suffer from …

Considered more efficacious and safer than traditional systemic drugs, biologic therapies
have dramatically improved the quality of life of patients with psoriasis. Recently, there has …

Introduction: Etanercept is a tumor necrosis factor alpha (TNF-α) inhibitor, which is approved
for the treatment of immune-mediated inflammatory conditions including rheumatoid arthritis …

Background Interferon‐alpha (IFN‐α) therapy is used to treat hepatitis C infection. The
exacerbation and occurrence of psoriasis in hepatitis C patients treated with IFN‐α is …

The association of chronic hepatitis C virus (HCV) infection with a wide spectrum of
cutaneous manifestations has been widely reported in the literature, with varying strength of …

The article presents a case study of a 46-year old male with HIV, hepatitis C and moderate
psoriasis was resistant to starting ultra violet B phototherapy due to scheduling issues. The …

Context: The efficacy and favorable safety profile of anti-tumor necrosis factor (TNF) agents
in the treatment of psoriasis and psoriatic arthritis (PsA) are supported by several …